• Vaccine Name: MSP3-CRM-Vac4All/ Alhydrogel®
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: Subunit vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: MSP3 (Thera et al., 2022): merozoite surface protein 3. Presents on the surface of merozoites, forms a protein complex with MSP1, MSP6 and MSP7.The protein complex is bound to receptors during the invasion of erythrocytic cells. (Coelho et al., 2019)
• msp3 gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: A protein-protein conjugate malaria and helminth TBV that uses a modified msp3 protein as an antigen and Alhydrogel (R) and CRM197 as adjuvant.

Human Response

• Host age: 18-55 years old (Thera et al., 2022)
• Vaccination Protocol: Phase I, Randomised, Dose-Finding Single Center Study, not started.
  Participants will be randomly put into three groups and will receive 3 doses of MSP3-CRM-Vac4All/ Alhydrogel®. Each group will receive different dose levels of MSP3-CRM-Vac4All/ Alhydrogel®: 3 µg, 10 µg, or 30 µg total MSP3-CRM197 conjugate protein (corresponding to 1, 3, 10 µg MSP3 protein). Participants will receive vaccination on day 1, day 28, and day 56 of the study. (Thera et al., 2022)